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PURPOSE. Sex hormones may be associated with primary open-angle glaucoma (POAG),
although the mechanisms are unclear. We previously observed that gene variants involved
with estrogen metabolism were collectively associated with POAG in women but not men;
here we assessed gene variants related to testosterone metabolism collectively and POAG risk.
METHODS. We used two datasets: one from the United States (3853 cases and 33,480 controls)
and another from Australia (1155 cases and 1992 controls). Both datasets contained densely
called genotypes imputed to the 1000 Genomes reference panel. We used pathway- and gene-
based approaches with Pathway Analysis by Randomization Incorporating Structure (PARIS)
software to assess the overall association between a panel of single nucleotide polymorphisms
(SNPs) in testosterone metabolism genes and POAG. In sex-stratified analyses, we evaluated
POAG overall and POAG subtypes defined by maximum IOP (high-tension [HTG] or normal
tension glaucoma [NTG]).
RESULTS. In the US dataset, the SNP panel was not associated with POAG (permuted P ¼ 0.77),
although there was an association in the Australian sample (permuted P ¼ 0.018). In both
datasets, the SNP panel was associated with POAG in men (permuted P  0.033) and not
women (permuted P ‡ 0.42), but in gene-based analyses, there was no consistency on the
main genes responsible for these findings. In both datasets, the testosterone pathway
association with HTG was significant (permuted P  0.011), but again, gene-based analyses
showed no consistent driver gene associations.
CONCLUSIONS. Collectively, testosterone metabolism pathway SNPs were consistently
associated with the high-tension subtype of POAG in two datasets.
Keywords: primary open-angle glaucoma, testosterone, genetics, pathway analysis
Primary open-angle glaucoma (POAG), a leading cause ofchronic progressive optic nerve degeneration worldwide,1
is a strongly age-related disease.2,3 Testosterone and estradiol
production decline with age,4,5 and accumulating evidence
suggests that the retina and optic nerve are sex hormone–
sensitive tissues6–9; thus, these sex hormones may be
implicated in the glaucomatous process. Postmenopausal
therapy with estrogen alone was associated with modest
reductions in IOP in a post hoc analysis from a randomized
clinical trial10 and with lower POAG risk in a large observa-
tional study11; yet, there is a gap in our understanding of the
role testosterone plays, if any, in the glaucomatous process.
Nongonadal sources of sex hormone precursors from the
adrenal gland provide dehydroepiandrosterone (DHEA), which
is converted to sex hormones in peripheral tissues (Fig.).12
Intracrinology refers to the synthesis of sex steroids in these
peripheral tissues from adrenal precursors.13 In fact, intracrine
metabolism accounts for essentially all androgen (and estro-
gen) synthesis in peripheral tissues for postmenopausal
women and up to approximately 40% of androgen synthesis
in aging men.13 Thus, biochemical factors that lead to
differences in intracrine metabolism may impact the availability
of sex hormones and influence disease processes related to
declining hormones. For example, various isoforms of 17-beta
hydroxysteroid dehydrogenase (17b HSD) are essential to the
local intracellular generation of testosterone and estradiol from
DHEA (Fig.).12 Interestingly, Coca-Prados and colleagues14
documented that the neuroendocrine secretory ciliary epithe-
lium expresses 17b HSD isoforms 2, 5, and 7, and these cells
actively metabolize androgen and other sex hormones.
However, genetic variants of 17b HSD have been little studied
specifically in relation to POAG.
Using a pathway analysis, we previously showed that,
collectively, genetic variants in estrogen metabolism enzymes
were associated with POAG in women and not men.15 Here,
we formed a custom testosterone metabolism genetic variant
panel in case-control datasets from the United States and
Australia/New Zealand to further evaluate if there is an
association overall, or stratified by sex, with POAG or POAG
subtypes defined by IOP. This panel focused on genes related
to the intracrine generation of testosterone, as local production
of sex steroid may be most relevant to the glaucomatous
process.
METHODS
Description of the Study Populations
The US data are derived from the National Eye Institute
Glaucoma Human Genetics Collaboration Heritable Overall
Operational Database (NEIGHBORHOOD), a genetic consor-
tium that includes the following eight independent datasets:
Massachusetts Eye and Ear Infirmary; National Eye Institute
Glaucoma Human Genetics Collaboration; Iowa; Marshfield;
the Ocular Hypertension Treatment Study; the Women’s
FIGURE. The testosterone pathway is depicted. Gene names are as
follows: AKR1C3-ALDO-KETO reductase family 1, member C3, also
known as HSD17B5; HSD17B 1, 2, 3, 7, 8, 12, 14–17 beta
hydroxysteroid dehydrogenase isoforms; CYP19A1: cytochrome
P450, family 19, subfamily A, polypeptide 1; SULT1E1: sulfotransferase
family 1E, estrogen-preferring, member 1; SULT1A1: sulfotransferase
family 1A, cytosolic, phenol-preferring, member 1; SRD5A1, 2, 3:
steroid 5-alpha-reductase 1, 2, 3; HSD3B 1, 2: 3-beta-hydroxysteroid
dehydrogenase 1, 2. AR, androgen receptor; ER, estrogen receptor;
DHT, dehydroxytestosterone.
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Genome Health Study; and two datasets from the Glaucoma
Genes and Environment Study: one genotyped on the
Affymetrix platform and the other genotyped on the Illumina
HapMap Series.16 The NEIGHBORHOOD dataset has a total of
3853 POAG cases and 33,480 controls. The Australian and New
Zealand data are derived from the Australian and New Zealand
Registry of Advanced Glaucoma (ANZRAG) and consist of 1115
advanced POAG cases and 1992 controls genotyped on the
Illumina Omni 1M or the OmniExpress array. Cases and
controls were drawn from Southern Adelaide Health Service/
Flinders University, University of Tasmania, Queensland Insti-
tute of Medical Research, and the Royal Victorian Eye and Ear
Hospital.17 All participants in both datasets were of European
ancestry. The institutional review boards of all participating
institutions approved this study.
Ophthalmic Characteristics of Cases and Controls
Across the eight datasets in NEIGHBORHOOD, cases and
controls lacked evidence of secondary IOP elevation on slit
lamp biomicroscopy, such as exfoliation syndrome, pigment
dispersion syndrome, or trauma. For cases and controls, slit
lamp examination or gonioscopy did not reveal evidence of
significant irido-trabecular meshwork apposition suggestive of
angle closure in either eye. For cases, fundus examination
revealed a cup-disc ratio (CDR) of at least 0.7 or an intereye
difference in CDR of at least 0.2. Each case had at least one eye
with visual field (VF) loss consistent with nerve fiber layer
dropout on a reliable test. In the absence of VF loss, the CDR
was 0.8 or higher in both eyes. Elevated IOP was not a criterion
for inclusion as a case or a control. Controls had a CDR of 0.6
or less in both eyes and a CDR intereye difference of 0.1 or less.
IOP at diagnosis was collected and used to categorize POAG
cases into high-tension glaucoma (HTG with IOP ‡22 mm Hg)
and normal tension glaucoma (NTG with IOP <22 mm Hg)
subtypes when available. The exact definition of POAG across
the eight NEIGHBORHOOD sites can be found in Supplemen-
tary Table 2 of Cooke Bailey et al.16
Advanced POAG cases in ANZRAG had best-corrected visual
acuity worse than 6/60 due to POAG or a reliable 24-2 VF with
a mean deviation worse than 22 db or at least two of four
central fixation squares affected with a pattern SD of <0.5%.
The less severely affected eye was also required to have signs
of glaucomatous disc damage with care taken to exclude
secondary glaucomas of all types. Unscreened participants
from the Australian Cancer Study (225 esophageal cancer
cases, 317 Barrett’s esophagus cases, and 552 controls) and
from a study of inflammatory bowel diseases (303 cases and
595 controls) were chosen as controls.
Genotyping Data and Imputation
Details regarding the genotyping of the US and Australian
datasets, including information about the genotyping platforms
and quality control measures, can be found in the Supplemen-
tal Note of Cooke Bailey et al.16 Estimated genotypic
probabilities for the loci in the US and Australian dataset
imputed to the 1000 Genomes Project reference panel (March
2012)18 were analyzed.
Generation of Genetic Data for the Testosterone
Pathway Analysis
The genome-wide associations between single nucleotide
polymorphism (SNP) allele dosage in relation to POAG were
analyzed with ProbABEL (GenABEL project developers; http://
www.genabel.org/)19 for NEIGHBORHOOD and SNPTEST
(University of Oxford; http://mathgen.stats.ox.ac.uk) in ANZ-
RAG.20,21 Logistic regression models adjusting for age, study-
specific eigenvectors, and study-specific covariates for each
dataset were evaluated. Using METAL (Center for Statistical
Genetics, University of Michigan; http://csg.sph.umich.edu/
abecasis/metal/index.html) we performed a meta-analysis to
assess SNP dosages in relation to POAG across the US
datasets.22 SNPs with imputation quality score >0.7 and minor
allele frequency >0.05 were carried forward for the US and
Australian datasets.16,17 For this work, we used the P values for
association with POAG from the 2974 gene variants in
NEIGHBORHOOD and the 2617 gene variants in ANZRAG
(with 2609 consensus SNPs between datasets) that were
attributable to testosterone metabolism for pathway analyses
(see Fig. for genes). The number of gene variants differed
slightly for each analysis.
Pathway Analysis by Randomization Incorporating
Structure (PARIS) Analysis
As part of the testosterone pathway, we chose to include genes
involved in the formation of androstenediol and testosterone,
because although they are made in the testes, they are also
formed from DHEA produced by the adrenal glands and then
undergo intracrine conversion to both androgens and estro-
gens in local tissues.12 We generated a custom SNP panel
derived from 16 genes across 12 chromosomes comprising the
testosterone metabolic pathway, as depicted in the Figure. We
submitted the P values from SNPs within 50 kB of the start and
end sites of these genes to PARIS (v2.4).23 We have previously
described PARIS23,24 and used a prior version of this software
to assess the estrogen metabolism pathway gene variants in
relation to POAG.15 PARIS derives a P value for association
between a given gene variant set and outcome of interest using
a permutation procedure. Specifically, it first creates a random
collection of SNPs with genomic features that mimic features
of the user-defined pathway (in this case, testosterone
metabolism), then compares the number of statistically
significant (P < 0.05) features within the user-defined pathway
to the random pathway. We chose to permute 10,000 times to
determine an overall likelihood of the random pathway
containing more significant features than the user-defined
one. For example, for the testosterone pathway SNP set
association with POAG among men in NEIGHBORHOOD,
PARIS reported 44 significant features; specifically, 27 of 238
‘‘simple features’’ (SNPs not in any linkage disequilibrium
block [LD block]) and 17 of 45 ‘‘complex features’’ (an LD
block with two or more SNPs) had P value less than 0.05 for
association with POAG. PARIS calculated a permuted P ¼
0.0001, indicating that only 1 of 10,000 random pathways with
genetic architectures similar to the testosterone pathway had a
higher significant feature count (>44 significant features with
P < 0.05). Initially, these analyses were carried out in men and
women together for the outcomes of overall POAG as well as of
the HTG and NTG subtypes. Subsequently, associations
between testosterone metabolism SNPs and POAG were
repeated in men and women separately. We also used the ‘‘- -
paris-details’’ flag to investigate specifically which of the genes
in the testosterone metabolism pathway were contributing to
the significant signal in the overall pathway. Analyses in
NEIGHBORHOOD were repeated in ANZRAG using a dataset-
specific testosterone SNP set, that is, SNPs in the ANZRAG
dataset located within 50 kB of the start and end sites of the 16
genes comprising the testosterone metabolism pathway,
because various platforms were used across studies, and
different sets of SNPs passed the quality control filters.
However, in secondary analysis, we did use the 2609
consensus SNPs between both datasets as the exposure of
interest in relation to the various glaucoma phenotypes. Finally,
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we explored whether our outcomes differed if we excluded
SNPs from five genes that coded for overlapping estrogen-
metabolizing enzymes (CYP19A1, SULT1E1, HSD17B1,
HSD3B1, and SRD5A1). Although unlikely, we also excluded
the four small genes with only one feature (HSD17B8,
SULT1A1, HSD3B1, and HSD3B2) to minimize any bias they
might introduce, as we were primarily interested in collections
of genes that worked in biochemical pathways in relation to
glaucoma outcomes.
RESULTS
The mean ages of cases and controls stratified by sex and POAG
subtype (HTG versus NTG) are provided in Tables 1 and 2 for
the US and Australian datasets, respectively. There is a
preponderance of female controls in the US dataset due to
the large size of the Women’s Genome Health Study,25 which
has a case-cohort design.
In NEIGHBORHOOD, the testosterone pathway was not
associated with POAG overall (permuted P¼ 0.77; Table 3) but
a significant association was noted in ANZRAG (permuted P¼
0.018; Table 3). In both datasets, the testosterone pathway was
associated with POAG overall among men (permuted P 
0.033) but not among women (permuted P ‡ 0.42). In both
datasets, the testosterone pathway was significantly associated
with HTG (permuted P  0.011), but there were inconsistent
results with respect to NTG (Table 3). Although the
testosterone pathway was associated with NTG in ANZRAG
(permuted P < 0.0001), it was not associated with NTG in
NEIGHBORHOOD (permuted P ¼ 1.00). These results were
essentially identical when evaluating only the overlapping
SNPs (as opposed to the dataset-specific SNP sets) between the
US and Australian datasets (see Supplementary Material).
Further stratification by sex for the POAG subtypes of HTG
and NTG as outcomes was not performed due to the smaller
sample sizes in both datasets. In both datasets, the relationship
between the testosterone pathway and POAG stratified by sex
was similar if the five genes that overlap between the estrogen
metabolism pathway15 and the testosterone pathway (CY-
P19A1, SULT1E1, HSD17B1, HSD3B1, and SRD5A1) were
excluded from analysis (data not shown). Furthermore, we also
performed an analysis deleting four small genes with only one
feature (HSD3B1, HSD3B2, HSD17B8, and SULT1A1), as such
genes will yield a P < 0.0001 if there is only one SNP in the
feature block with P < 0.05; the results of this analysis were
the same as the main results (see Supplementary Material).
Similar to the pathway approach, we tested the association
between the 16 testosterone pathway genes and our various
outcomes to determine the genes that were driving observed
associations. When comparing the US and Australian datasets,
there was no overlap in the significant driver genes with >1TA
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TABLE 2. The Mean Age and Distribution of POAG Cases and Controls
in the ANZRAG, Stratified by Sex and HTG or NTG
Sex n Age, y (SD)
POAG Males 563 59.9 (14.9)*
Females 592 61.1 (13.8)*
Controls Males 1270 58.4 (13.2)
Females 722 50.6 (15.1)
HTG Males 370 59.1 (15.3)*
Females 339 59.0 (13.9)*
NTG Males 143 62.2 (14.6)*
Females 187 64.1 (14.0)*
* Age and/or maximum known IOP were missing on 116 POAG
cases.
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feature (genes with permuted P < 0.05) responsible for the
associations between testosterone pathway and POAG in men
and women (Table 4). Furthermore, there were no overlapping
significant driver genes with >1 feature responsible for the
association between testosterone metabolism SNPs and HTG in
both the US and Australian datasets (Table 5). Several genes
were responsible for the relationship between the testosterone
SNP panel and NTG in ANZRAG, including AKR1C3,
HSD17B2, and HSD17B14 (permuted P for gene  0.036;
Table 5).
We also analyzed individual SNPs in the testosterone
metabolic pathway and the various outcomes. As expected,
no SNP achieved a P value that passed Bonferroni-corrected
significance level (2609 consensus SNPs evaluated for five
outcomes; thus, the new significance level is 3.83 10–6). The
complete results can be found in the Supplementary Material.
DISCUSSION
Very little is known about the role of testosterone metabolism
in POAG. This work assessed the relationship between gene
variants related to the intracrine testosterone metabolism and
POAG using two large datasets. In both datasets, we observed
that the assembled testosterone pathway SNP set was
consistently associated with HTG in two datasets. Further-
more, the pathway was consistently associated with POAG in
men but not in women.
Some of the testosterone pathway genetic associations
across the US and Australian datasets were not consistent.
Specifically, although the testosterone SNPs were not associ-
ated with POAG overall in the US dataset (permuted P¼ 0.77),
a significant association was found in the Australian dataset
(permuted P ¼ 0.018). Also, the relationship between the
testosterone SNP set and NTG was null in the US dataset,
whereas it was significant in the Australian dataset. Various
sensitivity analyses using only overlapping SNPs or excluding
genes predominately involved in estrogen metabolism did not
change the results that were consistent between the US and
Australian datasets. We suspect that the inconsistencies
between the datasets are due to differing sample size, as the
individual genes have very modest effects and no common
gene sets emerged as driving the pathway results replicating
TABLE 3. Relation Between the Testosterone Pathway Genetic Variants and POAG HTG and NTG With Sex-Stratified Results
NEIGHBORHOOD ANZRAG
n Testosterone Pathway n Testosterone Pathway
Cases Controls Permuted P Value Cases Controls Permuted P Value
POAG, overall 3853 33,480 0.77 1115 1992 0.018
POAG, males only 1693 4384 0.0001 563 1270 0.033
POAG, females only 2160 29,096 1 592 722 0.42
HTG, overall 1868 33,480 <0.0001 709 1992 0.011
NTG, overall 768 33,480 1 330 1992 <0.0001
P values <0.05 are shown in bold. All analyses were adjusted for age and site-specific principal components where appropriate. The number of
HTG and NTG cases are less than the total number of POAG cases in both NEIGHBORHOOD and ANZRAG because maximum known IOP was not
available.
TABLE 4. Gene Significance Within the Testosterone Pathway for POAG Patients Stratified by Sex in NEIGHBORHOOD (United States) and ANZRAG
(Australia)
Gene Chr
No. of
Simple Features
Based on US Data†
No. of
Complex Features
Based on US Data†
Gene P Value,* POAG
Gene P Value,*
POAG, Male
Gene P Value,*
POAG, Female
US Australia US Australia US Australia
HSD3B1 1 0 1 1 1 <0.0001 1 <0.0001 1
HSD3B2 1 0 1 1 1 1 1 1 1
HSD17B7 1 23 1 0.44 1 0.0014 1 0.43 0.53
SRD5A2 2 18 4 0.081 0.36 < 0.0001 1 1 0.21
SRD5A3 4 21 2 0.077 0.18 0.22 0.0021 0.21 0.031
SULT1E1 4 2 1 1 0.070 0.058 0.056 1 0.045
SRD5A1 5 22 2 1 0.0035 1 0.68 1 1
HSD17B8 6 0 1 1 1 1 <0.0001 <0.0001 1
HSD17B3 9 16 4 0.60 0.0088 1 0.021 0.59 0.70
AKR1C3 10 37 6 1 1 1 0.47 0.83 0.93
HSD17B12 11 13 3 0.0024 0.42 < 0.0001 1 1 0.012
CYP19A1 15 38 10 1 0.0002 0.42 0.092 0.95 0.087
HSD17B2 16 11 5 0.012 0.0037 0.014 0.051 1 0.0078
SULT1A1 16 0 1 < 0.0001 <0.0001 < 0.0001 <0.0001 1 <0.0001
HSD17B1 17 15 1 0.40 0.45 0.11 0.0008 1 1
HSD17B14 19 24 2 0.032 0.41 0.0013 0.35 0.59 1
P values <0.05 are shown in bold. Simple features refer to SNPs not in any LD block. Complex features refer to LD blocks with two or more
types of SNPs. Gene names can be found in the Figure legend. Chr, chromosome.
* All P Values are permuted P values as discussed in Methods.
† Genetic architecture is based on the US dataset considering POAG as the outcome. Genetic architecture for the Australian dataset and or
different outcomes varied only slightly, and these differences can be seen in the Supplementary Material.
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across the datasets; however, we cannot rule out different
disease definitions and environmental influences as the source
of the differences we report.
For the associations between the testosterone SNP set and
HTG in the US and Australian datasets, there was no common
genetic driver of the relationship between testosterone
metabolism SNPs and HTG. Different 17b HSD isoforms play
critical roles in the testosterone pathway and are involved in
the intracellular generation of markers that bind both androgen
and estrogen receptors (Fig.) via the interconversion of
androstenedione and testosterone as well as the interconver-
sion of estrone and estradiol. The literature would suggest that
the trabecular meshwork cells26 and retinal cells, including
retinal ganglion cells,9,27 are under estrogenic control, whereas
ocular adnexal tissues are predominately under androgenic
control.28 However, little is known of the relationship between
the various 17b HSD isoforms and glaucoma, particularly the
product of HSD17B14, which was first discovered in the
human retina29 and predicts a favorable response to tamoxifen
in estrogen receptor–positive breast cancer tissue.30 As for 17b
HSD isoforms 7 and 12, which were associated with HTG only
in the US dataset, they are involved in local production of
estradiol and feature prominently in the endoplasmic reticu-
lum,31 whose subcellular organelles are abundant in the
trabecular meshwork.32 More work is needed to understand
if and how testosterone metabolism and functional polymor-
phisms in the various 17b HSD enzymes contribute to
endoplasmic reticulum stress found in POAG.33
The association between the testosterone gene variant set
and POAG in men but not women in two datasets was a
notable finding. There is some evidence that declining estrogen
levels are linked to higher IOP in postmenopausal women34
and that in women, postmenopausal hormones might lower
IOP10,35 and be associated with lower glaucoma risk.11,36 In
contrast, there are scarce data of the impact of sex hormones
on health outcomes in aging males.37 There are, however,
sporadic case reports of syndromic male hypogonadism
associated with elevated IOP.38,39 Although specific genes in
the testosterone pathway that accounted for this apparent
sexual dimorphism were identified in both datasets (for
example, HSD17B7 in the US dataset and HSD17B1 in the
Australian dataset), no common gene drivers of this relation
were found. There are a myriad of reasons why gene drivers
common to the US and Australian datasets could not be found,
including the dissimilar sample sizes, the slight variation in
case-control ascertainment, and differences in genotyping
platforms that were used. Furthermore, differences in the
quality control and the imputation process generated different
SNP sets that conformed to our definition of testosterone gene
variants in the US and Australian datasets. Nonetheless, the lack
of consistent cross-study driver genes raises questions about
whether the relationship between testosterone metabolism
SNPs and POAG is truly sex specific. This is in contrast to the
relationship between the estrogen pathway SNPs and POAG,
where we found COMT to be a driver gene for the sexual
dimorphic association with glaucoma (associated with HTG in
women but not men) in two separate datasets.15
Study limitations include the fact that none of the individual
testosterone pathway SNPs were significantly associated with
POAG stratified by sex or with POAG subtypes of HTG/NTG
after correcting for multiple comparisons. Nonetheless, it is
well known that existing genome-wide association studies of
POAG are underpowered to find biologically meaningful gene
variants of modest effects due to the need to minimize false
discovery rates. In addition, the testosterone metabolic
pathway could be construed to extend beyond biochemical
pathways focused on intracrine production of sex steroids,
such as cholesterol biosynthesis.40 Finally, there is a lack of
evidence that a genetic signature associated with sex steroid
metabolism is related to varying concentrations of estradiol or
testosterone in cells relevant to POAG. Nonetheless, there is
accumulating evidence that exposures altering estrogen levels
modify the risk of POAG.11,36,41,42
Our study does have strengths, including the use of two
large datasets, the use of common imputed SNPs across the
genome, and the use of updated PARIS software with its
enhanced ability to refine gene margins. By including a second
dataset to compare findings, we were able to provide a more
careful interpretation of the relationship between the testos-
terone metabolic pathway and POAG and POAG subtypes
stratified by sex. By jointly analyzing association signals across
a large number of genetic variants, pathway analysis allowed
for identification of modest cumulative effects, which could
have been missed in standard analyses of individual variants.
In conclusion, in this study involving 40,440 participants
from two continents, we observed a significant relationship
between the testosterone metabolism SNPs collectively and
POAG among men but not among women. We also found that
these SNPs were associated with the high-tension subtype of
POAG in both the US and Australian dataset, although there
was no consensus on driver genes for these pathway
associations across the two datasets.
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